Sickle cell disease trials in Brazil
7 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- Where
- Campinas, Ribeirão Preto, Salvador, Sao Jose Rio Preto, São Luís, São Paulo
- Age
- 12 years to 100 years
- People
- 354 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06439082 - Phase 4Enrolling by invitationA Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
- Where
- Campinas, Porto Alegre, Rio de Janeiro, Santo André, São Paulo
- Age
- 18 years and over
- People
- 55 worldwide
- Run by
- Agios Pharmaceuticals, Inc.
See details and how to joinNCT05777993 · EU 2026-526243-35-00 - Phase 1/2Taking peopleA Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- Where
- Ribeirão Preto, São Paulo
- Age
- 12 years to 55 years
- People
- 161 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06546670 · EU 2024-515696-35-00 - Phase 3Taking peopleThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- Where
- Goiânia, Salvador, São José do Rio Preto, São Paulo
- Age
- 10 years to 65 years
- People
- 192 worldwide
- Run by
- Sanofi
See details and how to joinNCT06975865 - Phase 3Taking peopleA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- Where
- Distrito de Barão Geraldo - Campinas, Recife, Ribeirão Preto, Rio de Janeiro, São Paulo
- Age
- 12 years and over
- People
- 510 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06612268 · EU 2023-509175-16-00 - Phase 2/3Taking peopleA Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
- Where
- Recife, Ribeirão Preto, Rio de Janeiro, São, São José do Rio Preto, São Paulo
- Age
- 12 years to 64 years
- People
- 389 worldwide
- Run by
- Pfizer
See details and how to joinNCT05431088 · EU 2023-508766-14-00 - Phase 4Taking peopleRollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
- Where
- Ribeirão Preto, Salvador, São Paulo
- Age
- 6 months to 100 years
- People
- 130 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04657822 · EU 2024-510734-41-00